Abstract:PurposeTo enhance clinician’s decision-making by diagnosing hepatocellular carcinoma (HCC) in cirrhotic patients with indeterminate liver nodules using quantitative imaging features extracted from triphasic CT scans.Material and methodsWe retrospectively analyzed 178 cirrhotic patients from 27 institutions, with biopsy-proven liver nodules classified as indeterminate using the European Association for the Study of the Liver (EASL) guidelines. Patients were randomly assigned to a discovery cohort (142 patients (pts.)) and a validation cohort (36 pts.). Each liver nodule was segmented on each phase of triphasic CT scans, and 13,920 quantitative imaging features (12 sets of 1160 features each reflecting the phenotype at one single phase or its change between two phases) were extracted. Using machine-learning techniques, the signature was trained and calibrated (discovery cohort), and validated (validation cohort) to classify liver nodules as HCC vs. non-HCC. Effects of segmentation and contrast enhancement quality were also evaluated.ResultsPatients were predominantly male (88%) and CHILD A (65%). Biopsy was positive for HCC in 77% of patients. LI-RADS scores were not different between HCC and non-HCC patients. The signature included a single radiomics feature quantifying changes between arterial and portal venous phases: DeltaV-A_DWT1_LL_Variance-2D and reached area under the receiver operating characteristic curve (AUC) of 0.70 (95%CI 0.61–0.80) and 0.66 (95%CI 0.64–0.84) in discovery and validation cohorts, respectively. The signature was influenced neither by segmentation nor by contrast enhancement.ConclusionA signature using a single feature was validated in a multicenter retrospective cohort to diagnose HCC in cirrhotic patients with indeterminate liver nodules. Artificial intelligence could enhance clinicians’ decision by identifying a subgroup of patients with high HCC risk.Key Points• In cirrhotic patients with visually indeterminate liver nodules, expert visual assessment using current guidelines cannot accurately differentiate HCC from differential diagnoses. Current clinical protocols do not entail biopsy due to procedural risks. Radiomics can be used to non-invasively diagnose HCC in cirrhotic patients with indeterminate liver nodules, which could be leveraged to optimize patient management.• Radiomics features contributing the most to a better characterization of visually indeterminate liver nodules include changes in nodule phenotype between arterial and portal venous phases: the “washout” pattern appraised visually using EASL and EASL guidelines.• A clinical decision algorithm using radiomics could be applied to reduce the rate of cirrhotic patients requiring liver biopsy (EASL guidelines) or wait-and-see strategy (AASLD guidelines) and therefore improve their management and outcome.

A Radiomics Signature to Identify Malignant and Benign Liver Tumors on Plain CT Images.

CT-Based Radiomics for the Recurrence Prediction of Hepatocellular Carcinoma after Surgical Resection

Radiomics-Based Classification of Tumor and Healthy Liver on Computed Tomography Images

Radiomics Study for Differentiating Focal Hepatic Lesions Based on Unenhanced CT Images

Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules

Differentiation of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Pulmonary Adenocarcinoma by Radiomics

Radiomics approach to distinguish between benign and malignant soft tissue tumors on magnetic resonance imaging

Radiomics Analysis on Noncontrast CT for Distinguishing Hepatic Hemangioma (HH) and Hepatocellular Carcinoma (HCC)

Radiomic Signature as a Diagnostic Factor for Classification of Histologic Subtypes of Lung Cancer

A T2 Weighted Imaging-based Radiomics Nomogram for the Classification of Hepatic Blood-rich Lesions: Hepatocellular Carcinoma and Benign Liver Lesions

Machine Learning Radiomics Signature for Differentiating Lymphoma versus Benign Splenomegaly on CT

Radiomics-based Automated Machine Learning for Differentiating Focal Liver Lesions on Unenhanced Computed Tomography

Classification of malignant and benign liver tumors using a radiomics approach

CT radiomics analysis discriminates pulmonary lesions in patients with pulmonary MALT lymphoma and non-pulmonary MALT lymphoma

Radiomics as a non-invasive adjunct to Chest CT in distinguishing benign and malignant lung nodules

CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma

Radiomic signature: a non-invasive biomarker for discriminating invasive and non-invasive cases of lung adenocarcinoma

Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis.

Development and Validation of CT-Based Radiomics Signature for Overall Survival Prediction in Multi-organ Cancer

CT-based conventional radiomics and quantification of intratumoral heterogeneity for predicting benign and malignant renal lesions

Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma from Pancreatic Ductal Adenocarcinoma